|
US20030027216A1
(en)
|
2001-07-02 |
2003-02-06 |
Kiernan Urban A. |
Analysis of proteins from biological fluids using mass spectrometric immunoassay
|
|
AU2001247951A1
(en)
|
2000-02-07 |
2001-08-14 |
Roche Diagnostics Corporation |
Novel cationic amphiphiles
|
|
US20070026394A1
(en)
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
|
US20030072794A1
(en)
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
|
KR100909681B1
(ko)
|
2000-12-01 |
2009-07-29 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
WO2002059621A2
(en)
|
2001-01-24 |
2002-08-01 |
Bayer Corporation |
Regulation of transthyretin to treat obesity
|
|
US7514099B2
(en)
|
2005-02-14 |
2009-04-07 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
US20030170891A1
(en)
|
2001-06-06 |
2003-09-11 |
Mcswiggen James A. |
RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20030124616A1
(en)
|
2001-06-21 |
2003-07-03 |
Jacobsen Donald W. |
Homocysteinylated transthyretin
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
BRPI0313202A8
(pt)
|
2002-08-05 |
2016-08-16 |
Atugen Ag |
Formas adicionais para interferir com as moléculas de rna
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP1556684A4
(en)
|
2002-11-01 |
2008-01-23 |
Univ Colorado Regents |
QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION
|
|
US8090542B2
(en)
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
AU2004220556B2
(en)
|
2003-03-07 |
2009-05-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
EP1608735A4
(en)
|
2003-04-03 |
2008-11-05 |
Alnylam Pharmaceuticals |
RNAI CONJUGATES
|
|
CN101291653B
(zh)
|
2003-07-16 |
2012-06-27 |
普洛体维生物治疗公司 |
脂质包封的干扰rna
|
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
CA2569419A1
(en)
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
EP1781593B1
(en)
|
2004-06-07 |
2011-12-14 |
Protiva Biotherapeutics Inc. |
Cationic lipids and methods of use
|
|
EP1766035B1
(en)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
WO2005120583A2
(en)
|
2004-06-14 |
2005-12-22 |
Wisconsin Alumni Research Foundation |
Method for preventing or treating cardiac hypertrophy
|
|
US20080038227A1
(en)
*
|
2004-08-04 |
2008-02-14 |
Ignacio Torres Aleman |
Animal model of neurodegenerative diseases, the procedure for producing the model and applications thereof
|
|
BRPI0520207A2
(pt)
|
2004-12-08 |
2012-09-25 |
Revision Therapeutics Inc |
uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
|
|
CN1683559A
(zh)
*
|
2005-02-28 |
2005-10-19 |
上海交通大学 |
精神分裂症相关基因ttr的多态性位点及其应用
|
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ， インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
|
|
US7915230B2
(en)
|
2005-05-17 |
2011-03-29 |
Molecular Transfer, Inc. |
Reagents for transfection of eukaryotic cells
|
|
WO2007012191A1
(en)
|
2005-07-27 |
2007-02-01 |
Protiva Biotherapeutics, Inc. |
Systems and methods for manufacturing liposomes
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｅｇ５遺伝子発現の抑制のための組成物および方法
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
EP2695608B1
(en)
|
2006-10-03 |
2016-11-23 |
Arbutus Biopharma Corporation |
Lipid containing formulations
|
|
GB0704764D0
(en)
|
2007-03-12 |
2007-04-18 |
Electrophoretics Ltd |
Isobarically labelled reagents and methods of their use
|
|
EP2173358B1
(en)
|
2007-06-22 |
2015-10-21 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
|
EP2238251B1
(en)
|
2007-12-27 |
2015-02-11 |
Protiva Biotherapeutics Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
EP2224912B1
(en)
|
2008-01-02 |
2016-05-11 |
TEKMIRA Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
WO2009134487A2
(en)
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
|
WO2009100390A2
(en)
|
2008-02-08 |
2009-08-13 |
Mayo Foundation For Medical Education And Research |
Classifying amyloidosis
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
US20110237646A1
(en)
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
SG10201809460SA
(en)
|
2008-10-20 |
2018-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
DK2355851T3
(en)
|
2008-11-10 |
2018-06-25 |
Arbutus Biopharma Corp |
Newly known lipids and compositions for release of therapeutic agents
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
CA2760776C
(en)
|
2009-05-05 |
2019-07-09 |
Alnylam Pharmaceuticals, Inc. |
Lipid compositions for the delivery of therapeutic agents
|
|
CA2764609C
(en)
|
2009-06-10 |
2018-10-02 |
Alnylam Pharmaceuticals, Inc. |
Improved cationic lipid of formula i
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
KR20120050429A
(ko)
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
|
|
WO2011056883A1
(en)
|
2009-11-03 |
2011-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
|
|
US20130281510A1
(en)
|
2010-03-29 |
2013-10-24 |
Kumamoto University |
siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
|
|
US20230340473A1
(en)
|
2010-03-29 |
2023-10-26 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
|
ES2625689T3
(es)
|
2010-04-29 |
2017-07-20 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión de transtiretina
|
|
AU2011302152B2
(en)
|
2010-09-15 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
EP3564393A1
(en)
|
2011-06-21 |
2019-11-06 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
HK1200191A1
(en)
|
2011-11-18 |
2015-07-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
WO2013075035A1
(en)
|
2011-11-18 |
2013-05-23 |
Alnylam Pharmaceuticals |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
WO2013166041A1
(en)
|
2012-05-01 |
2013-11-07 |
The Trustees Of Columbia University In The City Of New York |
Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
|
|
CA2879683C
(en)
|
2012-08-03 |
2023-02-14 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
TW201610151A
(zh)
*
|
2013-09-23 |
2016-03-16 |
阿尼拉製藥公司 |
治療或預防與甲狀腺素運載蛋白相關疾病之方法
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
IL314045A
(en)
*
|
2013-12-12 |
2024-09-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
LT3185957T
(lt)
|
2014-08-29 |
2022-09-26 |
Alnylam Pharmaceuticals, Inc. |
Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
|
|
EP4029859A1
(en)
|
2014-11-21 |
2022-07-20 |
Bsim Therapeutics, S.A. |
2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
|
|
PL3329002T3
(pl)
|
2015-07-31 |
2021-04-19 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
|
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
|
WO2020069055A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
WO2021041884A1
(en)
|
2019-08-30 |
2021-03-04 |
Alnylam Pharmaceuticals, Inc. |
Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
KR20220152270A
(ko)
|
2020-03-06 |
2022-11-15 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
|
|
JP2024518374A
(ja)
|
2021-05-03 |
2024-05-01 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|